Research programme: antibacterials - Novita Healthcare/Valevia

Drug Profile

Research programme: antibacterials - Novita Healthcare/Valevia

Alternative Names: AVX 13616; AVX 13619; Vancomycin-resistant enterococci (VRE) therapeutics - Novita Healthcare; VRIs - Novita Healthcare

Latest Information Update: 24 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Avexa
  • Developer Novita Healthcare
  • Class Amino acids; Naphthalenes; Small molecules
  • Mechanism of Action Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bacterial infections; Clostridium infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Australia (Intraperitoneal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Australia (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Clostridium-infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top